Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JCAR 014

Next Previous
X
Search
Drug Profile

JCAR 014

Alternative Names: 4-1BB-modified CAR CD8+ central memory and CD4+ T lymphocyte therapy - Juno Therapeutics; anti-CD19-4-1BB-zeta modified CAR CD8+ central memory and CD4+ T lymphocyte therapy - Juno Therapeutics; anti-CD19/4-1BB/zeta modified CAR CD8+ central memory and CD4+ T lymphocyte therapy - Juno Therapeutics; JCAR-021; JCAR014

Latest Information Update: 19 Apr 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Fred Hutchinson Cancer Research Center
  • Developer AstraZeneca; Fred Hutchinson Cancer Research Center; Juno Therapeutics; National Cancer Institute (USA)
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 23 Mar 2024 Fred Hutchinson Cancer Center in collaboration with Juno Therapeutics terminates a phase I trial in Precursor cell lymphoblastic leukaemia-lymphoma in USA due to slow enrollment and end of funding) (IV) (NCT03103971)
  • 08 Jun 2023 Updated efficacy data from a phase I/II trial in haematological malignancies presented at the 28th Congress of the European Haematology Association (EHA-2023)
  • 10 Dec 2022 Updated Efficacy and adverse events data from a phase I trial in Precursor cell lymphoblastic leukaemia-lymphoma presented at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top